| This week's sponsor is SynteractHCR. | | | |
Featured Story | | | Wednesday, August 30, 2017 Eli Lilly and Incyte say they are planning to refile their FDA-rejected arthritis candidate baricitinib before the end of January, setting up a possible approval in the middle of 2018. |
|
|
Top Stories Wednesday, August 30, 2017 The U.K. life sciences sector has called for the government to make changes to help grow Big Biotechs and attract thousands of researchers. Industry leaders put together the wish list to influence an upcoming deal between the sector and an increasingly interventionist government. Wednesday, August 30, 2017 Armo Biosciences has raised $67 million to expand its late-phase immuno-oncology program and move an anti-PD-1 antibody into the clinic. The West Coast biotech signed up new Chinese backers and returned to existing investors such as Celgene and GV to put together the financing round. Wednesday, August 30, 2017 Flagship Pioneering’s quiet oncology upstart Torque Therapeutics has filed a $21 million raise as it lands in Kendall Square. Wednesday, August 30, 2017 Abbott has released a software security update to protect its cardiac pacemakers from hacking. The firmware update is intended to fix a cybersecurity weakness that allowed hackers to affect the battery life and pacing of 465,000 devices implanted in patients in the U.S. Wednesday, August 30, 2017 AstraZeneca is taking the next step at a new plant in the U.K. where it makes Zoladex, spending $50 million on a packaging line for the prostate cancer drug. But the drugmaker's small investment drew big attention from Brexit watchers trying divine what it means for the politically charged issue. Wednesday, August 30, 2017 In a historic day for cancer treatment and the larger biopharma industry, Novartis notched an FDA approval for its CAR-T treatment tisagenlecleucel, to be marketed as Kymriah, to treat pediatric and young adult patients with a form of acute lymphoblastic leukemia. Resources Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. 2nd Strategic Partnerships for Drug Repurposing October 26-27, 2017 | Boston, MA Now Accepting Applications: Fierce Innovation Awards Life Science Edition FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London 11th Digital Pharma East October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 